Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations

The objectives of the proposed study are to investigate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and prliminary efficacy of XH-S004 in moderate to severe COPD patients with a stale standards of care (SOC).

Participants needed: 81
Trial details
Phase: Phase 1Age: 40-80Biological sex: AllType: InterventionalSponsor: S-INFINITY Pharmaceuticals Co., LtdUpdated: Jun 25, 2025Locations: 1
Eligibility criteria

Sign the informed consent form (ICF); [+9]

Have a primary diagnosis of asthma as determined by the investigator; [+3]

Read more
Status: Recruiting

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally

Participants needed: 24
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: S-INFINITY Pharmaceuticals Co., LtdUpdated: May 18, 2025Locations: 1
Eligibility criteria

Male or female with aged ≥18 years old; [+6]

Subjects with laboratory evidence of bone marrow failure during the screening pe... [+6]

Read more
Status: Not yet recruiting

A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

The purpose of this study is to find out if XH-S004 can reduce pulmanary exacerbation over a 24-week treatment duration in participants with non-cystic fibrosis bronchiectasis.

Participants needed: 231
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: S-INFINITY Pharmaceuticals Co., LtdUpdated: May 20, 2025Locations: 1
Eligibility criteria

Understand the procedures and methods of this trial and sign a written informed... [+6]

Have a primary diagnosis of chronic obstructive pulmonary disease (COPD) or asth... [+4]

Read more